HCPLive

Post-operative Recovery Program Aids Community Hospital Outcome

FRIDAY, July 25, 2014 (HealthDay News) -- Implementation of an enhanced recovery after surgery (ERAS) colorectal program is feasible in a community hospital setting and significantly improves outcomes, according to a study published online July 23 in JAMA Surgery.

Cristina B. Geltzeiler, MD, from the Oregon Health and Science University in Portland, and colleagues assessed practice patterns and patient outcomes for all elective colon and rectal resection cases performed in 2009 (prior to ERAS implementation), 2011, and 2012. The ERAS program involves multidisciplinary efforts from anesthesia, preadmission, nursing, and surgery staff.

The researchers found that over the study period the use of laparoscopy increased from 57.4 to 88.8% (P < 0.001) and was accompanied by a significant decrease in length of stay (LOS; 6.7 versus 3.7 days; P < 0.001), without an increase in 30-day readmission rate (P = 0.49). There were decreases in use of patient-controlled narcotic analgesia (P < 0.001) and duration of use (P = 0.02). There was a trend toward decreased ileus (P = 0.02) and intra-abdominal infection (P = 0.24). Colorectal cancer diagnosis was not significantly associated with LOS, 30-day readmission rates, ileus, and intra-abdominal infection (all P > 0.05).

"Length of stay reductions resulted in an estimated cost savings of $3,202 per patient (2011) and $4,803 per patient (2012)," the authors write.

Abstract
 
Full Text (subscription or payment may be required)

 
Copyright © 2014 HealthDay. All rights reserved.

Most Popular

Recommended Reading

The assumption used to be that after a liver transplant patients would need to take immunnosuppressive drugs for years, even for life. A team of German researchers say that for about half of their adult patients, that is no longer true.
As good news about new treatments for hepatitis C infections continues to dominate the International Liver Congress, Texas researchers today reported more success with sofosbuvir and daclatasvir.
One cure for polycystic liver disease is a liver transplant—but since the disease is not fatal (the liver continues to do its job despite the problems the condition causes for patients), physicians face a treatment dilemma. A Belgian team offers an objective way to make the decision.
Video Interview: Vinood Patel, PhD, PGCHE, fHEA, FRSC, University of Westminster, London, UK, shared valuable insight regarding chronic alcoholic demographics and biomarkers on the horizon at The International Liver Congress 2015.
$vAR$